VRVirginie Rieu

Virginie Rieu

*This is an algorithmically generated author record based on publicly available information.

Virginie Rieu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anti‐ ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune‐Mediated TTP

    by Marie Robert, Arthur Mageau, Ygal Benhamou, François Provôt, Jehane Fadlallah, Lionel Galicier, Elie Azoulay, Hafid Ait‐Oufella, Tomas Urbina, Pascale Poullin, et al.

    Current triplet regimens associating therapeutic plasma exchange (TPE), immunosuppression with corticosteroids and rituximab, and caplacizumab have dramatically improved the outcome of immune‐mediated thrombotic thrombocytopenic purpura (iTTP). However, nearly half of the patients require extended caplacizumab treatment (i.e., > 30 days) due to persistent ADAMTS13 deficiency, raising cost and tolerance concerns. Therefore, we investigated whether anti‐ADAMTS13 antibodies titer and their trajectory during the acute phase of the disease could predict ADAMTS13 improvement (i.e., activity ≥ 20% before day‐30 post‐TPE). From a cohort of 286 patients receiving the triplet regimen, we identified on diagnosis a cut‐off value for anti‐ADAMTS13 IgG antibodies of 90.5 U/mL, with a modest discriminating ability (AUC: 0.57) for predicting long‐term response, precluding its use to guide therapeutic strategies. Nonetheless, the analysis of anti‐ADAMTS13 IgG antibodies titer trajectory from diagnosis revealed that the proportion of iTTP patients with ADAMTS13 activity improvement was higher in patients who decreased (Dec+) their antibodies titer within the 7–14 days interval post‐TPE compared to those without decrease (Dec−) (65% vs. 25% of cases, respectively, p < 0.001), a finding confirmed in a validation cohort ( N = 51). These results highlight the possibility of intensifying immunosuppression in an early period post‐TPE to shorten time to ADAMTS13 activity recovery. Close monitoring of anti‐ADAMTS13 antibodies titer may guide immunomodulation strategies, including additional courses of B‐cell depleting agents when appropriate.


  • Efficacy of bortezomib in non‐IgM type I cryoglobulinaemic vasculitis: a single‐centre retrospective case series

    by Hervé Lobbes, Vincent Grobost, Richard Lemal, Virginie Rieu, Guillaume Le Guenno, Marc Ruivard

    Introduction: Treatment of non‐IgM type I cryoglobulinaemic vasculitis (CV) is challenging. Corticosteroids are first‐line therapy, but relapses are frequent leading to therapeutic escalation. Bortezomib is a proteasome inhibitor with rapid effect on monoclonal component. However, its use in non‐IgM type I CV has been barely reported.Objective: To assess the efficacy of bortezomib in non‐IgM type I CV.Method: Single‐centre case series of four patients with non‐IgM type I CV treated with bortezomib monotherapy.Results: Two men and two women, 60‐84 years old, received bortezomib monotherapy. Monoclonal component was IgG‐λ (n = 2), IgA‐λ and IgG‐κ. Clinical features were necrotic rash (n = 3), synovitis (n = 3) and sensitive neuropathy (n = 2). CV was refractory to corticosteroids (n = 4), cyclophosphamide (n = 3) and rituximab (n = 2). Three patients experienced dramatic clinical improvement with undetectable cryoglobulin after three cycles (bortezomib 1.3 mg/m2 weekly). Each patient relapsed 4‐18 months after treatment discontinuation. Bortezomib was unsuccessful after four cycles in one patient. Bortezomib toxicity included one pneumonia and 1 case of worsening neuropathic pain.Conclusion: Bortezomib in monotherapy should be considered as a valuable option in refractory non‐IgM type I CV because of its swift efficacy and acceptable tolerance profile.


  • Open Access

    Regressive Aortic Valve and Infundibular Tumors During Idiopathic Hypereosinophilic Syndrome

    by Claire Dauphin, Pascal Motreff, Marc Ruivard, Virginie Rieu, Jean-Jacques Cloix, Dominique Lamaison, Jean Cassagnes, Jean-René Lusson